Cumberland Pharmaceuticals (CPIX) EV to EBIT (2010 - 2026)

Cumberland Pharmaceuticals has disclosed EV to EBIT across 17 years of filings, most recently posting 29.39 for Q2 2026.

• In Q2 2026, EV to EBIT fell 171.94% year-over-year to 29.39; the TTM figure through Jun 2026 stood at 9.65 (down 53.53% YoY), while the FY2025 annual figure was 17.1, down 643.46% from the prior year.
• EV to EBIT came in at 29.39 for Q2 2026 at Cumberland Pharmaceuticals, down from 11.94 in the prior quarter.
• In the past five years, EV to EBIT ranged from a high of 109.16 in Q2 2023 to a low of 51.9 in Q3 2022.
• Average EV to EBIT over 5 years is 3.69, with a median of 6.98 recorded in 2022.
• Year-over-year, EV to EBIT surged 1780.34% in 2023 and sank 16759.57% in 2025.
• Over 5 years, EV to EBIT stood at 5.39 in 2022, then jumped by 80.14% to 1.07 in 2023, then sank by 650.57% to 8.03 in 2024, then sank by 333.51% to 34.82 in 2025, then rose by 15.59% to 29.39 in 2026.
• Per Business Quant data, the three most recent EV to EBIT figures were 29.39 in Q2 2026, 11.94 in Q1 2026, and 34.82 in Q4 2025.